DK0907639T3 - Polymorfe forbindelser - Google Patents

Polymorfe forbindelser

Info

Publication number
DK0907639T3
DK0907639T3 DK97929654T DK97929654T DK0907639T3 DK 0907639 T3 DK0907639 T3 DK 0907639T3 DK 97929654 T DK97929654 T DK 97929654T DK 97929654 T DK97929654 T DK 97929654T DK 0907639 T3 DK0907639 T3 DK 0907639T3
Authority
DK
Denmark
Prior art keywords
pct
fluvastatin sodium
fluvastatin
sodium form
sec
Prior art date
Application number
DK97929654T
Other languages
English (en)
Inventor
Karol Horvath
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9602477A external-priority patent/SE9602477D0/xx
Priority claimed from SE9700751A external-priority patent/SE9700751D0/xx
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK0907639T3 publication Critical patent/DK0907639T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
DK97929654T 1996-06-24 1997-06-18 Polymorfe forbindelser DK0907639T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9602477A SE9602477D0 (sv) 1996-06-24 1996-06-24 Polymorphic compounds
SE9700751A SE9700751D0 (sv) 1997-03-03 1997-03-03 Polymorphic compounds
PCT/SE1997/001097 WO1997049681A1 (en) 1996-06-24 1997-06-18 Polymorphic compounds

Publications (1)

Publication Number Publication Date
DK0907639T3 true DK0907639T3 (da) 2003-06-23

Family

ID=26662685

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97929654T DK0907639T3 (da) 1996-06-24 1997-06-18 Polymorfe forbindelser

Country Status (11)

Country Link
US (1) US6124340A (da)
EP (1) EP0907639B1 (da)
JP (2) JP4282092B2 (da)
AT (1) ATE234282T1 (da)
AU (1) AU3366297A (da)
CY (1) CY2461B1 (da)
DE (1) DE69719755T2 (da)
DK (1) DK0907639T3 (da)
ES (1) ES2194202T3 (da)
PT (1) PT907639E (da)
WO (1) WO1997049681A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9902202D0 (sv) 1999-06-10 1999-06-10 Astra Ab Production of aggregates
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
DE60112956T2 (de) * 2000-10-31 2006-06-14 Ciba Sc Holding Ag Kristalline formen von fluvastatin sodium
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
CN1536999B (zh) * 2001-08-03 2012-08-08 西巴特殊化学品控股有限公司 氟伐他汀钠的晶形
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
DE10316087A1 (de) * 2003-04-08 2004-11-11 Ratiopharm Gmbh Polymorphstabilisierung von Fluvastatin-Natrium in Pharmazeutischen Formulierungen
WO2004096765A2 (en) * 2003-05-01 2004-11-11 Morepen Laboratories Ltd. A novel crystalline polymorph of fluvastatin sodium and a process for preparing it
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
US7368468B2 (en) * 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
US7368581B2 (en) * 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Process for the preparation of fluvastatin sodium crystal from XIV
KR20070094805A (ko) * 2003-06-18 2007-09-21 테바 파마슈티컬 인더스트리즈 리미티드 플루바스타틴 나트륨 결정형 ｘｉｖ, ｌｘｘｉｉｉ,ｌｘｘｉｘ, ｌｘｘｘ 및 ｌｘｘｘｖｉｉ, 이의 제조 방법,이를 포함하는 조성물 및 이를 사용하는 방법
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
US7432380B2 (en) 2003-10-16 2008-10-07 Ciba Specialty Chemicals Corp. Crystalline form of Fluvastatin sodium
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
US7241800B2 (en) 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
WO2006008656A2 (en) * 2004-07-21 2006-01-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Oatp-c gene c463a polymorphism underlies variable response of statin therapy
US7371906B2 (en) * 2004-08-24 2008-05-13 Eastman Kodak Company Process for photo-oxidative stability improvements
WO2006021967A1 (en) * 2004-08-26 2006-03-02 Biocon Limited Process for the preparation of fluvastatin sodium form a.
WO2006030304A2 (en) * 2004-09-17 2006-03-23 Ranbaxy Laboratories Limited Novel forms of fluvastatin sodium, processes for preparation and pharmaceutical compositions thereof
CA2583312A1 (en) * 2004-10-05 2006-04-13 Biocon Limited Process for the preparation of amorphous fluvastatin sodium
US7795451B2 (en) * 2005-02-11 2010-09-14 Jubilant Organosys Limited Polymorphic forms of fluvastatin sodium and process for preparing the same
WO2006109147A1 (en) * 2005-04-12 2006-10-19 Glenmark Pharmaceuticals Limited Substantially pure amorphous fluvastatin, processes for its preparation and pharmaceutical compositions containing same
MX2007013286A (es) * 2006-02-27 2008-03-07 Teva Pharma Formas novedosas de sodio de fluvastatina y preparacion de ellas.
EP1847529B1 (en) 2006-04-20 2009-05-20 F.I.S. Fabbrica Italiana Sintetici S.P.A. Process for the preparation of Fluvastatin Sodium salt
CN101250153B (zh) * 2008-02-26 2013-09-18 深圳信立泰药业股份有限公司 一种制备氟伐他汀钠晶型的工艺
PT2419407E (pt) * 2009-04-15 2013-01-28 Pharmathen Sa Processo melhorado para a preparação de fluvastatina e dos seus sais
CN114280181A (zh) * 2021-12-23 2022-04-05 浙江海翔川南药业有限公司 一种瑞舒伐他汀中间体及其有关物质的检测方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU204253B (en) * 1982-11-22 1991-12-30 Sandoz Ag Process for producing mevalonolactone analogues and derivatives and pharmaceutical compositions containing them
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them

Also Published As

Publication number Publication date
EP0907639A1 (en) 1999-04-14
ATE234282T1 (de) 2003-03-15
JP4282092B2 (ja) 2009-06-17
JP2000512992A (ja) 2000-10-03
AU3366297A (en) 1998-01-14
EP0907639B1 (en) 2003-03-12
WO1997049681A1 (en) 1997-12-31
US6124340A (en) 2000-09-26
ES2194202T3 (es) 2003-11-16
PT907639E (pt) 2003-06-30
DE69719755D1 (de) 2003-04-17
DE69719755T2 (de) 2003-11-20
CY2461B1 (en) 2005-06-03
JP2009149654A (ja) 2009-07-09

Similar Documents

Publication Publication Date Title
DK0907639T3 (da) Polymorfe forbindelser
LU91751I2 (fr) Asenapin et ses dérivés pharmaceutiquement acceptables (SYCREST®)
ES2123149T3 (es) Derivados de perhidroisoindol como antagonistas de la substancia p.
PL373903A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
DE69830504D1 (de) Antithrombotische mitteln
HU9601218D0 (en) Distamycin a analogue utilizable as antitumoral and antiviral medicines
BG106340A (en) Substituted oxoazaheterocyclyl compounds
ES2132415T3 (es) Nuevos derivados de 5-pirrolil-2-piridilmetilsulfinilbencimidazol.
HUT77925A (hu) Dihidrobenzofuránok, azokat tartalmazó gyógyászati készítmények és eljárás előállításukra
AU2672995A (en) {a}-annelated pyrrole derivatives and pharmaceutical uses thereof
AU3563695A (en) Novel piperidine derivatives with paf antagonist activity
BR0111102A (pt) Uso de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4pip eridinometanol ou sua pró-droga no tratamento de sintomas de demência e psicose induzida por dopamina
ES2076838T3 (es) Nuevo derivado de la isoindolinona, su preparacion y las composiciones farmaceuticas que le contienen.
BR9610175A (pt) Composto processo de preparação do composto composição farmacêutica e utilização do composto
DK0775113T3 (da) N-substituerede azabicycloheptan-derivater som neuroleptika osv.
NZ320522A (en) Piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same and a process for the preparation of the compounds
ES2140683T3 (es) Procedimiento para preparar compuestos de benzopirano.
DE69707509D1 (de) 2-phenyl-3-azoylbenzothiophene zur minderung des intraokularen drucks
FI963166A (fi) Uusia merkaptoasetyyliamididisulfidijohdannaisia, jotka ovat käyttökelpoisia enkefalinaasin ja ACE:n inhibiittoreina
EE9700327A (et) Meetod anhüdroekgoniini estrite valmistamiseks
DE69824410D1 (en) Antithrombosemittel
MXPA04006358A (es) Derivados del drechsleranol, procedimiento para su preparacion y su utilizacion.